BioArctic Partner Eisai Presents Real-World Lecanemab Data At AD/PD 2026 Showing 78.4% Of Early Alzheimer's Patients Continued Treatment At 18 Months

Benzinga Newsdesk www.benzinga.com Positive 50.3%

Neg 0% Neu 0% Pos 50.3%

Comments

No comments yet. Be the first!